Composition for the prevention or treatment of fibrosis

Fibrosis prevention and treatment materials based on histone acetyltransferase-inhibiting phenylphenol compounds

This technology is a composition for the prevention and treatment of fibrosis containing 2,6-dimethoxy-4-phenylphenol (acuparin), a natural active ingredient found in Rosaceae plants, or its salts as an active ingredient. It targets various fibrotic diseases, including pulmonary and renal fibrosis, by inhibiting the activity of histone acetyltransferase.

Fibrosis is a condition where abnormal collagen matrix accumulation following injury or inflammation impairs organ function. Idiopathic pulmonary fibrosis, in particular, has a poor prognosis, with an average survival of only 3 to 5 years after diagnosis. Steroid-based drugs and antioxidants have not shown clear efficacy, and long-term use is associated with systemic side effects and drug resistance, leaving a significant gap in approved therapeutic options.

This technology offers an approach to slowing the progression of fibrosis by using a natural phenyl-based compound to inhibit histone acetyltransferase, which regulates gene transcription. It can be applied to the development of treatments for pulmonary, hepatic, and renal fibrosis, as well as health supplements for fibrosis prevention and cosmetics for improving scleroderma, allowing for a product portfolio spanning pharmaceuticals, food, and cosmetics in a market lacking sufficient treatment options.

‍

‍

Key Features:

• Pharmaceutical composition for the prevention or treatment of fibrosis comprising 2,6-dimethoxy-4-phenylphenol or a pharmaceutically acceptable salt thereof as an active ingredient
• Composition targeting fibrotic diseases such as pulmonary, hepatic, renal, and cardiac fibrosis by inhibiting histone acetyltransferase activity
• Food composition for the prevention or improvement of fibrosis comprising 2,6-dimethoxy-4-phenylphenol or a salt thereof as an active ingredient
• Cosmetic composition for the prevention or improvement of scleroderma comprising 2,6-dimethoxy-4-phenylphenol or a salt thereof as an active ingredient

‍

This invention was developed with support from the Ministry of Science and ICT for research on the epigenetic control mechanisms of fibrotic diseases.

‍